In her reporting of the nasal vaccine landscape space, Jef Akst, managing editor of The Scientist, covered Meissa's intranasal live attenuated vaccine platform and our clinical trial data showing it can induce nasal antibodies with the potential to block transmission of respiratory viruses.
Excerpt from the article:
Rather than attenuate SARS-CoV-2, however, Meissa researchers decided to stick with their existing nasally delivered RSV construct but engineer it to display the SARS-CoV-2 spike protein. Interim results announced in October from the company’s Phase 1 trial showed that the vaccines induce nasal antibodies in people with and without prior exposure to the virus or a different vaccine.
“We have our eyes on all kinds of viruses now,” says Meissa founder and chief executive officer Marty Moore. “If we can establish immunity in the upper respiratory tract against a wide range of respiratory viruses . . . we could not just get back to where we were health-wise, but we could actually improve human health globally against a wide range of viruses. And that’s really exciting.”
Read the full article here.